Alai NN

This article has been peer reviewed and approved by Michael Fisher, MD, Professor of Medicine, Albert Einstein College of Medicine. Review date: January 2010.

Drs. Alai, Skinner, Nabili, Jeffes, Shahrokni, and Saemi report no conflict of interest. The authors discuss off-label use of botulinum toxin injections, carbamazepine, doxepin hydrochloride, gabapentin, oxcarbazepine, and thalidomide. Dr. Fisher reports no conflict of interest. The staff of CCME of Albert Einstein College of Medicine and Cutis^® have no conflicts of interest with commercial interest related directly or indirectly to this educational activity. Dr. Alai is Assistant Clinical Professor, Department of Dermatology and Department of Family Medicine; Dr. Skinner is Professor Emeritus, Department of Orthopaedic Surgery; Dr. Nabili is Assistant Clinical Professor, Department of Internal Medicine; Dr. Jeffes is Professor, Department of Dermatology; all at University of California, Irvine. Dr. Shahrokni is Associate Professor, University of California, San Diego. Dr. Saemi is a resident, Department of Radiology, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire.

Nili N. Alai, MD; Harry B. Skinner, MD, PhD; Siamak T. Nabili, MD, MPH; Edward Jeffes, MD, PhD; Seyed Shahrokni, MD; Arash M. Saemi, MD

This article has been peer reviewed and approved by Michael Fisher, MD, Professor of Medicine, Albert Einstein College of Medicine. Review date: January 2010.

Drs. Alai, Skinner, Nabili, Jeffes, Shahrokni, and Saemi report no conflict of interest. The authors discuss off-label use of botulinum toxin injections, carbamazepine, doxepin hydrochloride, gabapentin, oxcarbazepine, and thalidomide. Dr. Fisher reports no conflict of interest. The staff of CCME of Albert Einstein College of Medicine and Cutis^® have no conflicts of interest with commercial interest related directly or indirectly to this educational activity. Dr. Alai is Assistant Clinical Professor, Department of Dermatology and Department of Family Medicine; Dr. Skinner is Professor Emeritus, Department of Orthopaedic Surgery; Dr. Nabili is Assistant Clinical Professor, Department of Internal Medicine; Dr. Jeffes is Professor, Department of Dermatology; all at University of California, Irvine. Dr. Shahrokni is Associate Professor, University of California, San Diego. Dr. Saemi is a resident, Department of Radiology, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire.

Nili N. Alai, MD; Harry B. Skinner, MD, PhD; Siamak T. Nabili, MD, MPH; Edward Jeffes, MD, PhD; Seyed Shahrokni, MD; Arash M. Saemi, MD

This article has been peer reviewed and approved by Michael Fisher, MD, Professor of Medicine, Albert Einstein College of Medicine. Review date: January 2010.

Drs. Alai, Skinner, Nabili, Jeffes, Shahrokni, and Saemi report no conflict of interest. The authors discuss off-label use of botulinum toxin injections, carbamazepine, doxepin hydrochloride, gabapentin, oxcarbazepine, and thalidomide. Dr. Fisher reports no conflict of interest. The staff of CCME of Albert Einstein College of Medicine and Cutis^® have no conflicts of interest with commercial interest related directly or indirectly to this educational activity. Dr. Alai is Assistant Clinical Professor, Department of Dermatology and Department of Family Medicine; Dr. Skinner is Professor Emeritus, Department of Orthopaedic Surgery; Dr. Nabili is Assistant Clinical Professor, Department of Internal Medicine; Dr. Jeffes is Professor, Department of Dermatology; all at University of California, Irvine. Dr. Shahrokni is Associate Professor, University of California, San Diego. Dr. Saemi is a resident, Department of Radiology, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire.

Nili N. Alai, MD; Harry B. Skinner, MD, PhD; Siamak T. Nabili, MD, MPH; Edward Jeffes, MD, PhD; Seyed Shahrokni, MD; Arash M. Saemi, MD